Basic Principles and Clinical Relevance of the 2025 Update of the Drug Resistance Mutations in HIV-1
You must Login or Create Account in order to register for this event
Presenter
Moderator
Panelists
March 26, 2025
10:00 AM – 11:30 AM PTOverview
Assessment of Needs
This webinar will review the basic principles of HIV drug resistance mutations and highlight the IAS–USA 2025 Update of the Drug Resistance Mutations in HIV-1. It will provide an overview of the article, particularly focusing on understanding and applying the information in clinical practice. This webinar will feature a case-based panel discussion with experts on drug resistance mutations to highlight changes to the drug resistance mutations figure.
Learning Objectives
At the end of this webinar, participants will be able to:
- Describe the basic principles of HIV drug resistance mutations
- Explain how to understand and interpret the information presented on the IAS–USA 2025 Update of the Drug Resistance Mutations in HIV-1
- Identify recent updates to the IAS–USA 2025 Update of the Drug Resistance Mutations in HIV-1 and how they apply to the management of drug resistance in patients
Registration
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.
Individual registration is required in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, March 26, 2025, 10:30 AM (PT).
For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Presenter
Dr Wensing reported grants/grants pending to her institution from Gilead Sciences, Inc; consulting or advisor fees from Gilead Sciences, Inc, Merck Sharp & Dohme, and ViiV Healthcare/GSK; and non-cash provision of medicines, equipment, or administrative support to her institution from ARK Diagnostics, Inc. (Updated October 2, 2024)
Moderator
Dr Richman reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated December 19, 2024)
Panelists
Dr Ceccherini-Silberstein reported receiving payments to her institution from Gilead Sciences, Inc, Merck & Co. Inc, and ViiV Healthcare; and consulting fees from Gilead Sciences, Inc, Merck & Co. Inc, and ViiV Healthcare. (Updated November 11, 2024)
Dr Paredes reported funding to his institution from Merck & Co; receiving grants or contracts with Gilead Sciences, Inc, Merck & Co, Inc, PharmaMar, and Viiv Healthcare; receiving consulting fees from Gilead Sciences, Inc, Pfizer, Inc, Roche Therapeutics, Merck & Co, Inc, GSK, ViiV Healthcare, Eli Lilly and Company, AstraZeneca, Exevir, PharmaMar, and Atea Pharmaceuticals, Inc. (Updated November 11, 2024)
Dr Shafer reported receiving consulting fees from Gilead Sciences, Inc and GSK; and payment or honoraria from Gilead Sciences, Inc and GSK. (Updated November 11, 2024)
Planner/Reviewer
Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies (Updated January 29, 2025)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies (Updated January 29, 2025)
COW Board
The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/
CME Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.
Nursing Credits
Educational Review Systems is an approved approver of continuing nursing education by the ASNA, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.
This program is approved for 1.5 hours of pharmacotherapy credit.
Pharmacy Credits
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.5 contact hours (0.150 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-25-010-L02-P
Grant Support
This activity is funded by the IAS-USA through a generous donation by the Resistance Foundation. No commercial company or government funding was used to support the effort.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.